Magnetic resonance with gadoxetic acid for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis. Evaluation of its impact for the non-invasive diagnosis.

Fundació Clínic per a la Recerca Biomèdica0 个研究点开始时间: 2012年2月28日最近更新: 2017年2月6日

适应症

试验速览

暂无简介。

•- more than 18 years old
•- patient with diagnosis of liver cirrhosis Child Pugh A-B
•- Patients without previous hepatocellular carcinoma in whom ultrasound detects a suspiciuos hepatic lesion; solitary solid and well-defined nodule between 10 and 20 mm
•- patients in whom diagnosis of hepatocellular carcinoma is a clinical need prior to treatment indication
•- patient that agree to parcicipate signing informed consent form
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 1
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 1

•-Patients with poor liver function who would have undergone transplantation even without hepatocellular carcinoma diagnosis (Child-Pugh C)
•- patients with previous diagnosis of hepatocellular carcinoma
•-patients with significant comorbilities that could prevent the optimum therapeutic decision in case of positive diagnosis of hepatocellular carcinoma
•-patients with severe clotting alterations that contraindicate the fine-needle biopsy
•-Patients with chronic kidney disease or glomerular filtration rate < 30 ml/min
•- patients with contraindications to perform magnetic resonance imaging (pacemaker, claustrophobia...)
•- Known hypersensitivity to study drugs or excipients
•- pregnancy or breastfeeding

发起方

Fundació Clínic per a la Recerca Biomèdica